Metz Stefan W, Pijlman Gorben P
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA.
Laboratory of Virology, Wageningen University, Droevendaalsesteeg 1, 6708 NW, Wageningen, The Netherlands.
Methods Mol Biol. 2016;1426:297-309. doi: 10.1007/978-1-4939-3618-2_27.
Chikungunya virus is a reemerging human pathogen that causes debilitating arthritic disease in humans. Like dengue and Zika virus, CHIKV is transmitted by Aedes mosquitoes in an epidemic urban cycle, and is now rapidly spreading through the Americas since its introduction in the Caribbean in late 2013. There are no licensed vaccines or antiviral drugs available, and only a few vaccine candidates have passed Phase I human clinical trials. Using recombinant baculovirus expression technology, we have generated CHIKV glycoprotein subunit and virus-like particle (VLP) vaccines that are amenable to large scale production in insect cells. These vaccines, in particular the VLPs, have shown high immunogenicity and protection against CHIKV infection in different animal models of CHIKV-induced disease. Here, we describe the production, purification, and characterization of these potent CHIKV vaccine candidates.
基孔肯雅病毒是一种再度出现的人类病原体，可导致人类患上使人衰弱的关节炎疾病。与登革热病毒和寨卡病毒一样，基孔肯雅病毒通过伊蚊在城市流行周期中传播，自2013年末在加勒比地区出现以来，目前正在美洲迅速传播。目前尚无获批的疫苗或抗病毒药物，只有少数候选疫苗通过了I期人体临床试验。利用重组杆状病毒表达技术，我们制备了基孔肯雅病毒糖蛋白亚基疫苗和病毒样颗粒（VLP）疫苗，这些疫苗适合在昆虫细胞中大规模生产。这些疫苗，特别是病毒样颗粒，在基孔肯雅病毒诱发疾病的不同动物模型中显示出高免疫原性，并能预防基孔肯雅病毒感染。在此，我们描述了这些有效的基孔肯雅病毒候选疫苗的生产、纯化和特性。
